Back to Results

A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and a low residual β-cell function at baseline.

Study category: Diabetes & Hormone Disorders

Is this Study for You?

Let's Get Started!

Details
Age

Child to Adult

Type of Study

Treatment

Locations

Barbara Davis Center
University of Colorado Hospital

Principal Investigator
Andrea Steck,  MD

Andrea Steck, MD

Study ID

Protocol Number: 21-2474

More information available at ClinicalTrials.gov: NCT04628481

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers